文章：

前列腺导管内癌的分子改变

Molecular Alterations in Intraductal Carcinoma of the Prostate

原文发布日期：22 November 2023

DOI: 10.3390/cancers15235512

类型: Article

开放获取: 是

英文摘要：

Intraductal carcinoma of the prostate is most commonly associated with high-grade invasive prostate cancer. However, isolated IDC-P without adjacent cancer or high-grade cancer is also well known. Common genetic alterations present in IDC-P with adjacent high-grade prostate cancer are those described in high-grade tumors, such as PTEN loss (69–84%). In addition, the rate of LOH involvingTP53andRB1is significantly higher. IDC-P is common in the TCGA molecular subset ofSPOPmutant cancers, and the presence ofSPOPmutations are more likely in IDC-P bearing tumors. IDC-P without adjacent high-grade cancers are by far less common. They are less likely to have PTEN loss (47%) and rarely harbor an ERG fusion (7%). Molecular alterations that may predispose a person to the development of IDC-P include the loss ofBRCA2andPTENas well as mutations inSPOP. However, the causative nature of these genetic alterations is yet to be validated.

摘要翻译： 

前列腺导管内癌最常见于与高级别浸润性前列腺癌并存。然而，无邻近癌或高级别癌的孤立性导管内癌也已被广泛认知。伴有邻近高级别前列腺癌的导管内癌中常见的基因改变与高级别肿瘤中描述的基因改变一致，例如PTEN缺失（69-84%）。此外，涉及TP53和RB1的杂合性缺失发生率显著更高。导管内癌常见于TCGA分子分型中的SPOP突变癌症亚型，且携带导管内癌的肿瘤更可能存在SPOP突变。目前，无邻近高级别癌的导管内癌较为罕见。这类病例出现PTEN缺失的可能性较低（47%），且极少存在ERG融合（7%）。可能促使个体发生导管内癌的分子改变包括BRCA2和PTEN缺失以及SPOP突变。然而，这些基因改变与导管内癌发生的因果关系尚待进一步验证。

原文链接：

Molecular Alterations in Intraductal Carcinoma of the Prostate